GLP-1 Medicines in 2026: Questions to Ask Before Starting

1. Am I eligible, and what are we treating?

Start with the diagnosis and treatment goal. Many weight-management medicines are approved for adults with obesity, generally a body mass index of at least 30, or overweight, generally a BMI of at least 27, plus a weight-related condition. Those thresholds are not a universal rule for every product, age group or indication. Diabetes treatment follows different criteria, and a diabetes-branded drug is not automatically approved for weight management.

Eligibility also requires a safety review. Discuss pregnancy plans, breastfeeding, prior pancreatitis, gallbladder disease, kidney problems, severe stomach-emptying difficulties, diabetic eye disease and any history of disordered eating. Several commonly used products have contraindications involving a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Ordinary hypothyroidism is not the same diagnosis. Ask which warnings apply to your proposed prescription rather than assuming every medicine shares an identical label.

• What diagnosis supports treatment, and is this use FDA-approved or off-label?
• Which examinations or laboratory tests do I need, and what would change the recommendation?
• Could another treatment better fit my health history, preferences or budget?
• Do any current medicines duplicate this treatment or increase risks, especially insulin or sulfonylureas?

2. What benefits are realistic for this particular medicine?

Ask for expectations tied to the specific medicine, dose, indication and study population. Weight-loss results are usually reported as a percentage of starting weight over many months, not pounds lost each week. Across trials of commonly used obesity treatments, average losses have ranged from single-digit percentages to around 20%, but those studies are not interchangeable. People with diabetes may have different results, and some patients lose substantially less than a trial average.

Benefits can extend beyond weight, but they are product-specific. Certain products have FDA-approved indications related to cardiovascular risk, kidney outcomes or obstructive sleep apnea in defined populations. Do not assume that a benefit established for one product applies to every GLP-1 medicine. Agree on meaningful measures such as glucose control, mobility, sleep symptoms or blood pressure, alongside weight when relevant. Also ask when you will reassess whether treatment is helping enough to justify its burdens.

• What improvement is reasonable after dose escalation and after a year?
• Which benefits are supported for someone with my medical conditions?
• What happens if I cannot tolerate the dose used in clinical trials?
• How will we distinguish a temporary plateau from an inadequate treatment response?

3. How will we prevent and manage gastrointestinal effects?

Nausea, vomiting, diarrhea, constipation and abdominal discomfort are common concerns, particularly during dose escalation. Starting at the prescribed introductory dose and increasing according to the product's schedule can improve tolerability. Ask whether escalation should pause if symptoms persist; do not increase faster or improvise a lower dose yourself. Smaller meals, stopping when comfortably full and avoiding foods that reliably trigger symptoms may help. Repeated vomiting or inability to eat adequately needs clinical attention, not encouragement to push through.

Establish a contact plan before the first dose, including whom to call after hours. Vomiting and diarrhea can cause dehydration and worsen kidney function. Severe or persistent abdominal pain, especially with vomiting, needs prompt assessment for conditions such as pancreatitis or gallbladder disease. Symptoms suggesting a serious allergic reaction require emergency care. Tell surgical, anesthesia and endoscopy teams about treatment early: these medicines can delay stomach emptying, and procedure instructions should be individualized.

• What should I do for constipation, and which over-the-counter remedies are appropriate?
• Which symptoms mean call today, seek urgent care or call 911?
• What are the exact missed-dose instructions for this product?
• If illness interrupts treatment, do I need a lower restart dose rather than resuming my previous one?

4. How will I eat enough and protect strength?

Reduced appetite can make meal planning easier, but it can also leave patients short on protein, fluids and essential nutrients. Ask for a workable eating plan rather than a rigid list of forbidden foods. Protein needs depend on factors including age, body size, activity and kidney health, so a personalized target is more useful than a number copied from social media. A registered dietitian can help, particularly if nausea, dietary restrictions or a history of restrictive eating complicates treatment.

Weight loss can include lean tissue as well as fat. Discuss resistance exercise that fits your abilities, enough food to support daily function and ways to monitor strength. Rapid loss, persistent weakness, dizziness or regularly skipping meals deserves review. Supplements are not automatically necessary, and protein shakes should not quietly replace a varied diet without a plan. If you take insulin or a sulfonylurea, reduced intake and improved glucose control may require medication adjustments to prevent low blood sugar.

• What protein and fluid targets fit my medical conditions?
• Can I get a dietitian referral, and does insurance cover it?
• How should I adjust meals and glucose monitoring when appetite is very low?
• What changes in strength, energy or eating behavior should trigger an earlier visit?

5. Is this FDA-approved or compounded, and how do I verify?

FDA determinations that the semaglutide and tirzepatide injection shortages were resolved changed the shortage-based grounds for making copies. Do not assume an old shortage notice or transition deadline authorizes dispensing in August 2026. Check the FDA Drug Shortages database and its current GLP-1 compounding updates, including applicable enforcement policies or court-related changes. Ask the prescriber what lawful basis applies to your preparation. Lower price alone does not establish a patient-specific clinical difference.

FDA has warned about compounded-product dosing errors and semaglutide salt forms, including semaglutide sodium and acetate, which differ from the ingredient in approved drugs. Ask whether semaglutide base is used; added vitamins do not establish equivalence. Verify the pharmacy through its state board, and any claimed outsourcing-facility registration with FDA. For a vial, require written milligram, concentration, volume and syringe instructions.

6. What is the long-term treatment and follow-up plan?

Obesity and type 2 diabetes are chronic conditions, so treatment may continue for years when it remains beneficial, tolerable and accessible. Weight regain after stopping is common, and glucose control can worsen if diabetes treatment is withdrawn without a replacement. That does not mean everyone must stay on one medicine forever. It means the exit plan deserves as much attention as the starting dose.

Agree on follow-up during escalation and maintenance, including symptom review, relevant laboratory monitoring and adjustments to other medicines. Discuss pregnancy well before trying to conceive: semaglutide labeling recommends stopping at least two months before a planned pregnancy. Tirzepatide labeling advises people using oral hormonal contraceptives to switch to a nonoral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. Confirm current product-specific instructions.

• Who manages refills, monitoring and dose changes if my original clinician leaves?
• What is our plan if cost, pregnancy, side effects or supply interrupts treatment?
• Would maintenance involve the same medicine, another treatment or additional support?

7. What will insurance require, and what will I actually pay?

Coverage is specific to the plan, product and diagnosis. A plan may cover a medicine for diabetes but exclude obesity treatment, or require documentation supporting another approved indication. Before filling, ask the insurer for the current formulary entry, prior-authorization criteria and any step-therapy requirements. Find out whether renewal depends on documented response, ongoing visits or participation in a covered program.

Request a written estimate that separates the medicine from consultation fees, laboratory work, supplies and subscriptions. A first-month promotion is not an annual budget. Manufacturer savings programs have eligibility rules, expiration dates and limits; many exclude people enrolled in government insurance. Ask what you would owe after the deductible, after any coupon ends and if authorization is denied. Keep the approval notice and renewal date, and ask the clinic who handles appeals.

• Is my diagnosis covered, and which records must the prescriber submit?
• Must I use a particular pharmacy, or obtain a specific days' supply?
• What are the cancellation, refill and refund rules for a telehealth membership?
• Can we choose a sustainable alternative before an interruption becomes urgent?